Navigation Links
Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Date:1/13/2009

HOPKINTON, Mass., Jan. 13 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that on January 8, 2009 it entered into a securities purchase agreement (the "Agreement") with Robert Gipson for the private placement of 1,000,000 shares of common stock of the Company at a purchase price of $1.00 per share. The financing resulted in total gross proceeds of $1 million. In connection with the Agreement, Mr. Gipson agreed to the cancellation of a warrant previously issued to him to purchase 543,478 shares of common stock of the Company at a purchase price of $1.84 per share. The Company intends to use the net proceeds from this private placement to fund its research and development programs and otherwise for general corporate purposes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

In connection with the Agreement, the Company issued an additional 456,522 shares of its common stock to Mr. Gipson pursuant to a Letter Agreement (the "Letter Agreement") between the Company and Mr. Gipson dated November 20, 2008. The Letter Agreement provided that if the Company sold shares of its common stock at a price below $1.84, subject to certain exceptions, prior to December 31, 2009, Mr. Gipson would be entitled to receive, for no additional consideration, additional shares of common stock and warrants in accordance with a pre-determined formula. Under the Agreement, Mr. Gipson has waived his right to additional warrants.

The securities offered and sold by Alseres in this private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Ex
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
4. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
5. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
6. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
9. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
10. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
11. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014 /PRNewswire/ ... company focused on gynecologic disease, announced today that ... with investors including Oracle Investment Management, Jack ... Vermillion directors. Total proceeds were $10.5 million, before ... working capital and general corporate purposes. ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On ... law H.R. 83, the Omnibus and Continuing Resolution ... time, made hydrocephalus a condition eligible to receive ... (CDMRP) administered by the Department of Defense (DoD). ... its allies on Capitol Hill, is celebrating this ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... , , ST. LOUIS, ... SIAL ), and MIP Technologies AB announced today the launch of ... extraction of non-steroidal anti-inflammatory drugs (NSAIDs). , ... portfolio because it targets a critical area of public concern - ...
... Comprehensive tutorials on ... these invaluable resources. , ... WA (PRWEB) July 16, 2009 -- OpenHelix today announced the availability of new tutorial ... dbGaP resource is a database of genotypes and phenotypes with extensive variation ...
... , , , SEATTLE, ... its series A financing round. The infusion of capital assures the company of ... variety of cellulosic materials (such as algae, plants and food waste) into a ... part of the agreement, the lead investor has joined the board of Blue ...
Cached Biology Technology:Supelco(R) and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 2Supelco(R) and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 3New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 2New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 3
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... are obese, have type 2 diabetes or a family history ... pregnancies because of a study at Washington University School of ... mice, suggests that Metformin, the most commonly prescribed anti-diabetes drug, ... We found that embryos of insulin-resistant mice also ...
... and IC-MedTech Inc. has yielded an innovative liquid crystal technology ... effectively manage cancer and other diseases. The American Cancer Society ... be diagnosed this year. This crisis has caused the National ... death due to cancer by the year 2015. ...
... Sept. 6, 2007 Seattle Childrens Hospital will receive ... a new five-year, eleven-part grant awarded by the National ... $23.7 million grant will support the Northwest Genome Engineering ... Childrens Hospital Research Institute in partnership with the University ...
Cached Biology News:Drug could improve pregnancy outcomes in wider range of women with insulin resistance 2Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 2Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 3Seattle Children's Hospital leads $23.7 million NIH grant to study gene repair 2Seattle Children's Hospital leads $23.7 million NIH grant to study gene repair 3
... AVOID FREEZE/THAW CYCLES. An assay kit ... by Western blotting. PARP is an enzyme ... During apoptosis, PARP is cleaved by caspase-3. ... kDa to 85 kDa is a hallmark ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Open-slot design for ...
... is expressed in g per ml and is ... pH 6.8, of a 1 mg per ml ... concentration to agglutinate a 2% suspension of human ... at 25 C. Preparation Note: Affinity ...
... dispensers save space and organize gloves, ... garb. They are the perfect benchtop ... in labs, processing and manufacturing. Clear ... the particles they attract. Open-slot design ...
Biology Products: